News & Analysis on Clinical Trial Services & Contract Research And Development
Athira Pharma, Mark Litton
By Maggie Lynch
- Last updated on
The clinical-stage company focused on developing therapies for Alzheimer’s and Parkinson’s disease has appointed Mark Litton to COO.
Litton, co-founder of Alder Biopharmaceuticals where he served as chief business officer and treasurer for 14 years, will take on the role at Athira with experience in the life sciences industry. Before his time at Adler, Litton worked as VP of business development at Celltech Group and VP of business development at Chiroscience Group.
Leen Kawas, president and CEO of Athria said, “Mark’s experience will be key during this transformative stage of the company.”
Litton also commented, “I’m delighted to be joining Leen and Athira’s dedicated team focused on a first-in-class approach that may bring hope to those touched by Alzheimer’s and other neurodegenerative diseases.”